Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203

BEDMINSTER, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the publication of data from the Phase 1 portion of the EnACT (Encochleated...
August 10, 2020 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights

– ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment;...
August 04, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in the BTIG Virtual Biotech Conference 2020

BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
July 28, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2020 Financial and Operational Results on August 10, 2020

BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
June 30, 2020 16:15 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials

- Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021 - - EnACT remains on track for cohort progression in Q4 2020 - BEDMINSTER, N.J., June 30, 2020 (GLOBE...
May 26, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Jefferies Virtual Healthcare Conference

BEDMINSTER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...
May 11, 2020 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights

– ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management to host conference call...
May 04, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020

BEDMINSTER, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
April 28, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference

BEDMINSTER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
March 31, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States...